Continuous Glucose Monitoring May Benefit Adults with Type 2 Diabetes
Continuous glucose monitoring (CGM) was found to improve glucose control among adults with type 2 diabetes who received multiple daily insulin injections, according to a recent study.
In their randomized clinical trial, the researchers compared the hemoglobin A1c (HbA1c) levels of 79 participants with type 2 diabetes who were assigned to CGM and 79 participants with type 2 diabetes who were assigned to usual care. All participants received multiple daily insulin injections, and those assigned to CGM averaged 6.7 days of CGM use per week.
After 24 weeks, the mean HbA1c levels decreased from 8.5% at baseline to 7.7% in the CGM group and to 8.0% in the control group.
CGM-measured hypoglycemia and quality of life outcomes did not differ significantly between groups
“A high percentage of adults who received multiple daily insulin injections for type 2 diabetes used CGM on a daily or near-daily basis for 24 weeks and had improved glycemic control,” the researchers concluded. “Because few insulin-treated patients with type 2 diabetes currently use CGM, these results support an additional management method that may benefit these patients.”
—Melissa Weiss
Reference:
Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial [published online August 22, 2017]. Annals Intern Med. doi:10.7326/M16-2855.